Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 17
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19
Matthew M.Y. Lee, John J.V. McMurray
JAMA (2023) Vol. 329, Iss. 14, pp. 1155-1155
Open Access | Times Cited: 2
Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis
Leon Di Stefano, Malathi Ram, Daniel O. Scharfstein, et al.
Medicine (2023) Vol. 102, Iss. 23, pp. e33904-e33904
Open Access | Times Cited: 2
The valley of death: why Australia failed to develop clinically effective drugs in COVID‐19
Jennifer Martin
Internal Medicine Journal (2023) Vol. 53, Iss. 12, pp. 2175-2179
Open Access | Times Cited: 2
Steroid hormone receptors and regulation of ACE2 and COVID-19 disease outcomes
Morag J. Young, Karen E. Chapman
Elsevier eBooks (2023), pp. 129-145
Closed Access | Times Cited: 1
Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial
Vincent Rathkolb, Marianna Traugott, Andreas Heinzel, et al.
iScience (2023) Vol. 26, Iss. 11, pp. 108146-108146
Open Access | Times Cited: 1
Hypertension and COVID-19 — current state and prospects
И. В. Долгалев, Ю. Г. Самойлова, K. Yu. Maksimova, et al.
Arterial’naya Gipertenziya (Arterial Hypertension) (2023) Vol. 29, Iss. 6, pp. 557-567
Open Access | Times Cited: 1
Renin as a Prognostic and Predictive Biomarker in Sepsis: More Questions Than Answers?*
Emily See, James A. Russell, Rinaldo Bellomo, et al.
Critical Care Medicine (2024) Vol. 52, Iss. 3, pp. 509-512
Closed Access
COVID-19, inflammaging and immunosenescence: implications for cardiovascular disease
Zair Hassan, Muneeb Ullah, Varsha Kumari, et al.
International Journal of Surgery Global Health (2024) Vol. 7, Iss. 2
Open Access
“Every Cloud Has a Silver Lining”: How Three Rare Diseases Defend Themselves from COVID-19 and What We Have Learnt from It
Martina Cacciapuoti, Ilaria Caputo, Lucia Federica Stefanelli, et al.
Clinics and Practice (2024) Vol. 14, Iss. 2, pp. 614-618
Open Access
Cardiometabolic disease and COVID-19: A new narrative
Mohamad B. Taha, Bharat Narasimhan, Eleonora Avenatti, et al.
Elsevier eBooks (2024), pp. 365-375
Closed Access
Vasopressor Responsiveness 101: Prediction of Responsiveness to Angiotensin II Infusion*
James A. Russell
Critical Care Medicine (2024) Vol. 52, Iss. 8, pp. 1310-1313
Closed Access
The effect of pre-hospital use of RAS inhibitors on COVID-19 mortality
Rama Ibrahim
Journal of Investigative Medicine (2024) Vol. 72, Iss. 8, pp. 863-875
Closed Access
Beyond the Guidelines: Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19
Alison Leslie, Scott A. Chapman, Kateyln M. Tessier, et al.
(2024)
Closed Access
Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018–2022
Norazida Ab Rahman, Ee Vien Low, Audrey Huili Lim, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access
Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study
Ana Tomás, Björn Wettermark, Fredrik Nyberg, et al.
BMJ Open (2024) Vol. 14, Iss. 10, pp. e082209-e082209
Open Access
Treat or not treat COVID‐19 with combined renin–angiotensin system and neprilysin inhibition: Have we found a solution?
Insa E. Emrich, Michael Böhm
European Journal of Heart Failure (2024)
Open Access
[Review] Drug-induced causes of renal damage and dysfunction in patients with complicated COVID-19
Natalia Vadimov Teplova, Kermen Ivanovna Bairova, Evgeny Evsikov, et al.
(2023)
Open Access
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Katherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine (2023) Vol. 176, Iss. 5
Open Access
Evaluation and Treatment of Essential Hypertension: An Update
Debbie L. Cohen, Jordana B. Cohen, Raymond R. Townsend
Nephrology Self-Assessment Program (2022) Vol. 21, Iss. 4, pp. 284-295
Closed Access
Previous Page - Page 2

Scroll to top